As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

CVRX INC (CVRX:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

CVS Health Corporation, together with its subsidiaries, is a diversified health solutions company. The Company’s segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Its Health Care Benefits offer a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare supplement plans, and Medicaid health care management services. Its Health Services provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and diagnostic testing.

CVS Health Corporation

CVR Refining, LP is an independent downstream energy limited partnership with refining and related logistics assets that operates in the mid-continent region. The Company is a petroleum refiner. It owned and operated a complex full coking medium-sour crude oil refinery in Coffeyville, Kansas with a rated capacity of 115,000 barrels per calendar day (bpcd) and a complex crude oil refinery in Wynnewood, Oklahoma with a rated capacity of 70,000 bpcd capable of processing 20,000 bpcd of light sour crude oils (within its rated capacity of 70,000 bpcd), as of December 31, 2016. In addition, it also controlled and operated supporting logistics assets, including approximately 340 miles of active owned and leased pipelines, approximately 150 crude oil transports, a network of crude oil gathering tank farms, approximately 6.4 million barrels of owned and leased crude oil storage and over 4.5 million barrels of combined refined products and feedstocks storage capacity, as of December 31, 2016.

CVR Refining LP

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRX INC

Silvercorp Metals Inc. (Silvercorp) is a mining company producing silver, lead and zinc metals in concentrates from mines in China. The Company along with its subsidiaries is engaged in acquisition, exploration, development, and mining of mineral properties. Silvercorp operates several silver-lead-zinc mines, including Ying Mining District in Henan Province, China, Gaocheng (GC) silver-lead-zinc mine in Guangdong Province, China and BYP Gold-Lead-Zinc mine in Hunan Province. The Ying Mining District consists of several mines, including the SGX mine, HZG mine, TLP mine, HPG mine, LMW mine, LME mine and DCG mine. The Ying Property is approximately 240 kilometers (km) west-southwest of Zhengzhou, the capital city of Henan Province, and approximately 145 km southwest of Luoyang. The GC mine is located approximately 200 kilometers west of Guangzhou City, Guangdong Province, southern China, the permit covers an area of approximately 5.5 km2. The BYP Mine is located in Hunan Province.

Silvercorp Metals Inc

SPDR S&P 500 Value ETF (the Fund), formerly SPDR Dow Jones Large Cap Value ETF, seeks to closely match the returns and characteristics of the S&P 500 Value Index. The S&P 500 Value Index measures the performance of the large-capitalization value sector in the United States equity market. The Index consists of those stocks in the S&P 500 Index exhibiting the strongest value characteristics based on book value to price ratio; earnings to price ratio, and sales to price ratio. The selection universe for the S&P 500 Index includes all United States common equities listed on the New York Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) Global Select Market, NASDAQ Select Market and NASDAQ Capital Market with market capitalizations of $3.5 billion or more. The Fund's investment advisor is SSgA Funds Management, Inc.

SPDR Portfolio S&P 500 Value ETF

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. The Company’s product candidates include AT-007, AT-001, and AT-003. Its AT-007 is a central nervous system (CNS) penetrant ARI for the treatment of CNS rare diseases, including Galactosemia, sorbitol dehydrogenase (SORD) deficiency, and PMM2-CDG. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is being developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Applied Therapeutics Inc

Viracta Therapeutics, Inc. is a precision oncology company focused on the treatment and prevention of virus-associated cancers. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label phase II basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II trial for the treatment of EBV+recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its Vecabrutinib is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK). VRx-510 is its preclinical-stage PDK-1 inhibitor. It is also investigating in pre-clinical studies the use of its epigenetic drug candidate, nanatinostat. 

VIRACTA THERAPEUTICS INC

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s pipeline includes Buntanetap, ANVS405 and ANVS301. Its lead product candidate Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Additionally, Buntanetap was observed to protect nerve cells from dying in the brain of traumatic brain injury mice and to protect nerve cells from dying in the eye of glaucoma rats. ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia.

Back

CVRX

Buy

👑 Overview

📈

-12.98%

Annual Growth

🌏

1

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$13.25

How our community is investing

1

N/A

N/A

N/A

1092 days

CVRX investor breakdown

💵 Income of investors

100%

👶 Age of investors

100%

🙋 Legal gender of investors

100%

$2.99 USD

Find Out More

$40.86 USD

Find Out More

$1.30 USD

Find Out More

$1.46 USD

Find Out More

$13.39 USD

Find Out More

$67.64 USD

Find Out More

$10.49 USD

Find Out More

Buy